Does early intensive multifactorial treatment reduce total cardiovascular burden in individuals with screen-detected diabetes? Findings from the ADDITION-Europe cluster-randomized trial

Diabetic Medicine

Volumn 29, Issue 11, 2012, Pages

  Simmons, R K ^a   Sharp, S J ^a   Sandbaek A ^b   Borch Johnsen, K ^b,c   Davies, M J ^d   Khunti, K ^d   Lauritzen, T ^b   Rutten, G E H M ^e   van den Donk, M ^e   Wareham, N J ^a   Griffin, S J ^a  

^a MRC EPIDEMIOLOGY UNIT   (United Kingdom)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AMPUTATION; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DENMARK; DIABETES MELLITUS; EARLY INTERVENTION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; SCREENING; UNITED KINGDOM;

ADULT; AGED; AMPUTATION; CARDIOVASCULAR DISEASES; CLUSTER ANALYSIS; DENMARK; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; GREAT BRITAIN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NETHERLANDS; RISK FACTORS;

EID: 84867201468     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2012.03759.x     Document Type: Article

References (38)

1. UKPDS. Tight blood pressure control and risk of macrovascular and microvascular complications in type2 diabetes: UKPDS38. UK Prospective Diabetes Study Group. Br Med J (Clin Res Ed 1998; 317: 703-713.
2. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614-620.
3. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D et al.Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-1772.
4. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type2 diabetes. N Engl J Med 2008; 358: 580-591.
5. Simmons RK, Echouffo-Tcheugui JB, Griffin SJ. Screening for type2 diabetes: an update of the evidence. Diabetes Obes Metabol 2010; 12: 838-844.
6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type2 diabetes. N Engl J Med 2008; 359: 1577-1589.
7. National Screening Committee. Handbook for Vascular Risk Assessment, Risk Reduction and Risk Management. University of Leicester: National Screening Committee, 2008.
8. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbaek A et al.Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011; 378: 156-167.
9. Murphy SA, Antman EM, Wiviott SD, Weerakkody G, Morocutti G, Huber K et al.Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 2008; 29: 2473-2479.
10. Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol 2009; 54: 2358-2362.
11. LaRosa JC, Deedwania PC, Shepherd J, Wenger NK, Greten H, DeMicco DA et al.Comparison of 80 versus 10mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial). Am J Cardiol; 105: 283-287.
12. Tikkanen MJ, Szarek M, Fayyad R, Holme I, Cater NB, Faergeman O et al.Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. J Am Coll Cardiol 2009; 54: 2353-2357.
13. Nissen SE. Cardiovascular outcomes in randomized trials: should time to first event for 'hard' endpoints remain the standard approach?J Am Coll Cardiol 2009; 54: 2363-2365.
14. Scholte op Reimer WJM, Gitt AK, Boersma E, Simoons ML (eds). Cardiovascular Diseases in Europe. Sophia Antipolis, France: European Society of Cardiology, 2004.
15. Chen BE, Cook RJ. Tests for multivariate recurrent events in the presence of a terminal event. Biostatistics 2004; 5: 129-143.
16. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, Rutten G. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type2 diabetes detected by screening. Int J Obes Relat Metab Disord 2000; 24: S6-11.
17. Echouffo-Tcheugui JB, Simmons RK, Williams KM, Barling RS, Prevost AT, Kinmonth AL et al.The ADDITION-Cambridge trial protocol: a cluster-randomised controlled trial of screening for type2 diabetes and intensive treatment for screen-detected patients. BMC Public Health 2009; 9: 136.
18. Webb DR, Khunti K, Srinivasan B, Gray LJ, Taub N, Campbell S et al.Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type2 diabetes mellitus detected by screening. Trials 2010; 11: 16.
19. Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type2 diabetes: 1-year data from the ADDITION Netherlands study. Br J Gen Pract 2009; 59: 43-48.
20. Sandbaek A, Griffin SJ, Rutten G, Davies M, Stolk R, Khunti K et al.Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. Diabetologia 2008; 51: 1127-1134.
21. Sargeant LA, Simmons RK, Barling RS, Butler R, Williams KM, Prevost AT et al.Who attends a UK diabetes screening programme? Findings from the ADDITION-Cambridge study. Diabet Med 2010; 27: 995-1003.
22. van den Donk M, Sandbaek A, Borch-Johnsen K, Lauritzen T, Simmons RK, Wareham NJ, et al.Screening for Type2 diabetes. Lessons from the ADDITION-Europe study. Diabet Med 2011; 28: 1416-1424.
23. WHO. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Geneva: World Health Organization, 1999.
24. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type2 diabetes. N Engl J Med 2003; 348: 383-393.
25. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
26. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type2 diabetes (UKPDS33). Lancet 1998; 352: 837-853.
27. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
28. Royal College of General Practitioners in Denmark. Type2 Diabetes in General Practice - Diagnosis and Treatment. Copenhagen, Denmark: Royal College of General Practitioners in Denmark, 1999.
29. McIntosh A, Hutchison A, Home PD, Brown F, Bruce A, Damerell A et al.Clinical Guidelines and Evidence Review for Type2 Diabetes: Management of Blood Glucose. Sheffield: ScHARR, University of Sheffield, 2001.
30. Rutten GEHM, Verhoeven S, Heine RJ, De Grauw WJC, Cromme PVM, Reenders K. Dutch College of General Practitioners. Practice guideline diabetes mellitus type2. Huisarts Wetensch 1999; 42: 67-84.
31. NICE. Type2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care. London: National Institute for Health and Clinical Excellence, 2008.
32. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc 1989; 84: 1065-1073.
33. Metcalfe C, Thompson SG. Wei, Lin and Weissfeld's marginal analysis of multivariate failure time data: should it be applied to a recurrent events outcome?Stat Methods Med Res 2007; 16: 103-122.
34. Giorda CB, Avogaro A, Maggini M, Lombardo F, Mannucci E, Turco S et al.Recurrence of cardiovascular events in patients with type2 diabetes: epidemiology and risk factors. Diabetes Care 2008; 31: 2154-2159.
35. Doran T, Fullwood C, Gravelle H, Reeves D, Kontopantelis E, Hiroeh U et al.Pay-for-performance programs in family practices in the UK. N Engl J Med 2006; 355: 375-384.
36. Royal College of General Practitioners in Denmark. Type2 Diabetes in General Practice - An Evidence-Based Guideline. Copenhagen, Denmark: Royal College of General Practitioners in Denmark, 2004.
37. Rutten GEHM, de Grauw WJC, Nijpels G, Goudswaard AN, Uitewaal PJM, Van der Does FEE et al.Dutch guidelines on Type2 diabetes mellitus. Dutch College of General Practitioners. Huisarts Wetensch 2006; 49: 137-152.
38. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type2 diabetes. N Engl J Med J 2008; 359: 1577-1589.